Finasteride Side Effects (Libido, Depression, Post-Finasteride Syndrome) — What the Research Shows

Finasteride inhibits type II 5-alpha-reductase, the enzyme that converts testosterone into a stronger androgen, dihydrotestosterone (DHT). Lowering DHT in the hair follicles slows follicle miniaturization in androgenetic alopecia. At the same time, DHT has physiological functions in the prostate, skin and genital organs, and testosterone, part of which is no longer converted, stays at a normal or slightly higher level. Systemically, finasteride 1 mg does not lower testosterone — an important distinction, because the common belief that the drug ‘kills testosterone’ is untrue.

So why might it affect libido or mood? There are hypotheses. 5-alpha-reductase enzymes also take part in the synthesis of neurosteroids in the brain (for example allopregnanolone), which modulate GABA-A receptors and can influence mood and anxiety. Inhibiting this pathway is a biologically plausible mechanism, but for now it rests mainly on preclinical studies and small human studies; it is not a proven causal mechanism of adverse effects in patients. The same goes for sexual function: lowering DHT in genital tissues could theoretically affect erection and sensitivity, but clinical evidence confirming this mechanism is limited.

How to read this? First, in the population of older men treated for prostatic enlargement (usually finasteride 5 mg) the risk of sexual problems was clearly increased. Second, in men with hair loss (younger, lower 1 mg dose) the effect was not significant, but the confidence intervals are wide — for erectile dysfunction from 0.20 to 2.25 — meaning the data are compatible both with no effect and with a several-fold rise in risk. Lack of significance is not proof of safety but a lack of statistical power to settle the question.

In addition, the randomized trials in hair loss typically lasted from several months to two years, excluded people with existing sexual problems and were conducted in settings in which the research team detected adverse effects more (or less) thoroughly than in ordinary practice. They therefore do not describe higher-risk patients well, nor symptoms that persist after stopping the drug.

This study is often cited as proof that sexual problems after finasteride ‘are all in the head’. That is an abuse of it. Its conclusion is narrower: the way a patient is informed significantly affects the number of reported symptoms, so in trials and in practice part of them result from expectations. The study concerned men with prostatic enlargement on a 5 mg dose and says nothing about symptoms that persist long after stopping. Nocebo explains part, but need not explain everything.

Practical conclusion: it is worth knowing the possible risks, but there is no reason to expect problems as a certainty. If symptoms do appear, however, they must not be dismissed or automatically written off as ‘just nocebo’ — that requires a conversation with a doctor and possibly stopping the drug.

How to reconcile these two results? The first study showed an increased risk of a depression diagnosis, the second no significant association in the pooled analysis. The answer is that observational studies are distorted by differences between treated and untreated people (more comorbidities, more frequent contact with doctors and hence more frequent detection of depression) and by the fact that most data concern older men with prostatic enlargement rather than young finasteride users with hair loss. A Canadian cohort study of 93,197 men aged ≥66 also showed an increased risk of depression (HR 1.94 in the first 18 months) and self-harm, but not suicide, and the absolute increase in events was 17 (self-harm) and 237 (depression) per 100,000 patient-years.

For a person considering finasteride this means something concrete: one cannot claim that the drug is free of risk to mood, but neither can one claim that the risk is large. A fair summary is: the scale of the risk is unknown, it is rare for serious events, and early recognition of symptoms is important — especially in people with a history of depression or anxiety.

What follows from these papers? First, there is a group of men who describe sexual, psychological and physical symptoms that persist after stopping finasteride. In a follow-up of the same group, most (96% of 54 people) still reported symptoms after a mean of 14 months. Second, we do not know how often the phenomenon occurs, because the studies relied on people who reported the problem themselves. Third, the literature has no uniform diagnostic criteria for PFS and no confirmed mechanism.

For people who want to avoid risk for these reasons, alternatives exist: topical or oral minoxidil (we discuss them in separate articles), supportive therapies and microneedling, and consciously accepting hair loss. None of them acts exactly like finasteride on follicle miniaturization, so this is a decision with a trade-off that must be made with full knowledge.

It is worth adding that both enthusiastic accounts of ‘nothing wrong after 10 years’ and dramatic forum stories are anecdotes prone to selection bias: those the drug suits rarely write about it online, while those who suffer write a great deal. Neither group gives a reliable estimate of frequency — which is why prospective studies are needed.

Finasteride remains an effective and, for most people, well-tolerated drug — and at the same time one in which an honest conversation about risk is part of the treatment. The safest approach is to start it after discussing your psychological and sexual history, with realistic expectations and a plan to reassess after a few months, and not to hesitate to stop it if worrying symptoms appear. This is not a reason for fear, but it is a reason for attentiveness — and when in doubt, it is better to ask a doctor than to rely on forums.